# Remibrutinib in Real-world Clinical Practice

> **NCT07358364** · — · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 3280 (estimated)

## Conditions studied

- Chronic Spontaneous Urticaria

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07358364
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-02
- **Primary completion:** 2031-10-30
- **Final completion:** 2031-10-30
- **Target enrollment:** 3280 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07358364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07358364, "Remibrutinib in Real-world Clinical Practice". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07358364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*